1. Home
  2. LTH vs IOVA Comparison

LTH vs IOVA Comparison

Compare LTH & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Life Time Group Holdings Inc.

LTH

Life Time Group Holdings Inc.

HOLD

Current Price

$26.94

Market Cap

5.7B

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.76

Market Cap

968.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTH
IOVA
Founded
1992
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
968.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
LTH
IOVA
Price
$26.94
$2.76
Analyst Decision
Strong Buy
Buy
Analyst Count
10
12
Target Price
$38.65
$10.45
AVG Volume (30 Days)
2.0M
11.3M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
88.46
N/A
EPS
1.28
N/A
Revenue
$2,913,442,000.00
$250,425,000.00
Revenue This Year
$15.07
$60.94
Revenue Next Year
$10.88
$60.85
P/E Ratio
$20.60
N/A
Revenue Growth
15.77
175.62
52 Week Low
$21.49
$1.64
52 Week High
$34.99
$8.15

Technical Indicators

Market Signals
Indicator
LTH
IOVA
Relative Strength Index (RSI) 59.27 66.72
Support Level $25.60 $2.08
Resistance Level $26.73 $2.60
Average True Range (ATR) 0.62 0.15
MACD 0.05 0.04
Stochastic Oscillator 81.62 96.38

Price Performance

Historical Comparison
LTH
IOVA

About LTH Life Time Group Holdings Inc.

Life Time Group Holdings Inc is a lifestyle and leisure brand offering health, fitness, and wellness experiences to a community. It is engaged in designing, building, and operating distinctive and large, multi-use sports and athletic, professional fitness, family recreation, and spa centers in a resort-like environment, principally in residential locations of metropolitan areas in the United States and Canada.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: